GBM102 GBM Model
GBM102-derived PDX model is at the forefront of preclinical Brain Cancer drug discovery. Its crucial role lies in its ability to accurately mimic patient responses, providing a reliable platform for evaluating the efficacy and safety of drug candidates. Researchers depend on GBM102 PDX to make informed decisions, prioritize promising therapies, and streamline their path to clinical trials. This model significantly accelerates the drug development process by identifying viable treatment options and optimizing their potential for Brain Cancer patients.
Model Details
Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM102
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Temozolomide), Radiation (2Gy)
WES: Yes
RNAseq: Yes
Methylation: Yes
PDX Treatment: Yes
Patient Treatment History: Yes
GBM102 Survival
Survival of orthotopic intracranial implanted GBM102 in Nu/Nu mice (n=5)
